Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

New Horizon Health Ltd (HKEX:6606) climbed HK$57.34 (215%) to HK$84 in its first day of trading this week after becoming the first diagnostics company to list on the Hong Kong stock exchange’s biotech chapter. The Qiming Venture Partners-backed company raised $263 million through the sale of 76.6 million shares at HK$26.66; it ended the week at HK$81.60.

Alta closes third NextGen fund
Alta Partners raised $275 million in the first and final closing of its NextGen Fund III, which the firm intends to invest in therapeutics and healthcare services companies. The San Francisco and Denver-based firm’s holdings include anti-infectives play Vir Biotechnology Inc. (NASDAQ:VIR) and antibody company Allakos Inc. (NASDAQ:ALLK)...